23andMe Explores Strategic Options as Financial Struggles Deepen
The genetic testing company faces significant liquidity challenges, leadership turmoil, and declining revenue as it considers restructuring or a potential sale.
Overview
- 23andMe announced it is exploring strategic alternatives, including a potential sale, restructuring, or asset licensing, to address its financial difficulties.
- The company reported an 8% year-over-year decline in consumer services revenue for Q3 2025, contributing to ongoing liquidity concerns.
- Leadership challenges have intensified, with seven board members resigning in September 2024 due to disagreements with CEO Anne Wojcicki over the company's direction.
- 23andMe's stock has plummeted 98% since 2021, with its market valuation dropping below $100 million from a peak of $6 billion.
- The company has engaged Moelis & Company and Goodwin Procter LLP to guide its exploration of strategic options but has not guaranteed any outcomes.